MEDIVIR AB – INTERIM REPORT JANUARY – SEPTEMBER 2020

On November 11, 2020 MEDIVIR AB reported that – INTERIM REPORT JANUARY – SEPTEMBER 2020 (Press release, Medivir, NOV 11, 2020, View Source;interim-report-january–september-2020-301169439.html [SID1234570648])

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Continued focus on MIV-818

July – September
Significant events during the quarter

In July, a research collaboration was initiated with the Drug Discovery and Development Platform (DDD) at SciLifeLab on potential inhibitors of SARS CoV-2. Through the collaboration, DDD will get access to Medivir’s unique proprietary protease-targeted compound library.
Financial summary for the quarter

Net turnover amounted to SEK 1.1 (1.7) million.
The profit before interest, tax, depreciation and amortization (EBITDA) amounted to SEK 5.2 (-22.0) million. Basic and diluted earnings per share amounted to SEK 0.19 (-0.95) and SEK 0.19 (-0.95) respectively.
Cash flow from operating activities amounted to SEK -17.1 (-31.8) million.
Liquid assets and short-term investments at the end of the period amounted to SEK 82.7 (158.5) million.
January – September
Financial summary

Net turnover amounted to SEK 12.5 (7.3) million.
The loss before interest, tax, depreciation and amortization (EBITDA) amounted to SEK -27.9 (-88.6) million. Basic and diluted earnings per share amounted to SEK -1.30 (-3.76) and SEK -1.30 (-3.76) respectively.
Cash flow from operating activities amounted to SEK -57.1 (-125.3) million.
Liquid assets and short-term investments at the end of the period amounted to SEK 82.7 (158.5) million.
Significant events after the end of the quarter

In October Dr. Tom Morris was appointed interim Chief Medical Officer. Dr. Morris will report to CEO Yilmaz Mahshid and be a member of Medivir’s management team.
Conference call for investors, analysts and the media
The Interim Report January – September 2020 will be presented by Medivir’s President & CEO, Yilmaz Mahshid.

Time: Tuesday, November 10, 2020, at 14.00 (CET).